Basics |
Fulgent Genetics, Inc.
Fulgent Genetics Inc is a technology company offering genetic testing to provide physicians with clinically actionable diagnostic information used to improve the overall quality of patient care.
|
IPO Date: |
September 29, 2016 |
Sector: |
Healthcare |
Industry: |
Medical Diagnostics and Research |
Market Cap: |
$671.87M |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$0.91 | 2.92%
|
Avg Daily Range (30 D): |
$0.27 | 1.32%
|
Avg Daily Range (90 D): |
$0.32 | 1.61%
|
Institutional Daily Volume |
Avg Daily Volume: |
.3M |
Avg Daily Volume (30 D): |
.23M |
Avg Daily Volume (90 D): |
.23M |
Trade Size |
Avg Trade Size (Sh.): |
63 |
Avg Trade Size (Sh.) (30 D): |
47 |
Avg Trade Size (Sh.) (90 D): |
45 |
Institutional Trades |
Total Inst.Trades: |
1,747 |
Avg Inst. Trade: |
$1.83M |
Avg Inst. Trade (30 D): |
$.96M |
Avg Inst. Trade (90 D): |
$.95M |
Avg Inst. Trade Volume: |
.04M |
Avg Inst. Trades (Per Day): |
1 |
Market Closing Trades |
Avg Closing Trade: |
$1.95M |
Avg Closing Trade (30 D): |
$.87M |
Avg Closing Trade (90 D): |
$.93M |
Avg Closing Volume: |
44.58K |
|
|
News |
Aug 1, 2025 @ 8:26 PM
Why Fulgent Genetics Stock Was Crushing It on Frid...
Source: Eric Volkman
|
Jul 15, 2025 @ 11:41 PM
Bragar Eagel & Squire, P.C. Is Investigating GoHea...
Source: Bragar Eagel & Squire, P.C.
|
Jul 1, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating GoHea...
Source: Bragar Eagel & Squire, P.C.
|
Jun 23, 2025 @ 4:53 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: N/A
|
Jun 10, 2025 @ 1:00 AM
Bragar Eagel & Squire, P.C. Is Investigating Semle...
Source: N/A
|
Financials |
|
TTM |
Q2 2025 |
Q1 2025 |
Basic EPS
|
|
|
|
Diluted EPS
|
|
|
|
Revenue
|
$ 303.22M
|
$ 81.8M
|
$ 73.46M
|
Gross Profit
|
$ 121.4M
|
$ 34.44M
|
$ 28.35M
|
Net Income / Loss
|
$ -52.04M
|
$ -19.26M
|
$ -11.9M
|
Operating Income / Loss
|
$ -72.72M
|
$ -19.71M
|
$ -19.8M
|
Cost of Revenue
|
$ 181.82M
|
$ 47.37M
|
$ 45.12M
|
Net Cash Flow
|
$ 22.9M
|
$ 20.6M
|
$ 12.14M
|
PE Ratio
|
|
|
|
|
|
|